Pirofsky B
Ann N Y Acad Sci. 1981;377:779-85. doi: 10.1111/j.1749-6632.1981.tb33775.x.
The therapeutic effect of goat anti-human thymocyte antiserum globulin (ATG) was assessed in ten patients with myasthenia gravis. Five patients had undergone prior thymectomy. All subjects had far-advanced, debilitating and progressing disease poorly responsive to classic anticholinesterase therapy. Prolonged, low dose ATG therapy was used with 1.0-2.6 grams/protein administered intramuscularly over a 28-73 period. Depression of cellular immunity was observed with anti-thymocyte antiserum was more profound in patients with a prior thymectomy. Therapeutic responses of varying degrees were noted in 8 out of 10 patients. Completion of a course of ATG and discontinuation of the drug did not lead to acute relapse states. Follow-up examinations for over five years have been maintained. A mean remission period of approximately two years was observed. It is suggested that this therapy deserves further evaluation. Subjects with prior thymectomy and progressive disease may represent the most ideal candidates.
对10例重症肌无力患者评估了山羊抗人胸腺细胞抗血清球蛋白（ATG）的治疗效果。5例患者此前接受过胸腺切除术。所有受试者病情都已发展到晚期，衰弱且呈进行性，对传统抗胆碱酯酶疗法反应不佳。采用了长时间低剂量的ATG疗法，在28至73天的时间内肌肉注射1.0 - 2.6克蛋白质。观察到细胞免疫受到抑制，抗胸腺细胞抗血清对曾接受胸腺切除术的患者影响更为显著。10例患者中有8例出现了不同程度的治疗反应。完成一个疗程的ATG治疗并停药并未导致急性复发状态。已持续进行了五年多的随访检查。观察到平均缓解期约为两年。建议对这种疗法进行进一步评估。此前接受过胸腺切除术且病情呈进行性的受试者可能是最理想的候选对象。
